A Phase 2, Open-Label, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF)
ID Number 13-1807Principal Investigator(s)
John O. Mascarenhas
Department(s) or Division(s)
Hematology and Medical Oncology
To evaluate the efficacy of two different dose schedules of PRM-151 in intermediate- 1, intermediate-2, or high risk subjects with PMF, post-PV MF, or post ET-MF who are not receiving therapy for MF, and in subjects with PMF, post-PV MF, or post ET-MF on a stable dose of ruxolitinib for at least three months.
Recruiting Patients: Yes